LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "gejc" as a keyword



Abstract 5890: Distinct differences in microbial enrichment and diversity identified between gastric and gastroesophageal junction adenocarcinoma

Sign Up to like & get
recommendations! Published in 2023 at "Cancer Research"

DOI: 10.1158/1538-7445.am2023-5890

Abstract: Objective: The microbiome is associated with the pathogenesis and progression of disease in gastric cancer (GC). Eradication of Helicobacter pylori has reduced overall GC incidence, however, gastroesophageal cancer (GEJC) continues to increase. While there are… read more here.

Keywords: gejc; diversity; differences microbial; microbial enrichment ... See more keywords

Real-world treatment patterns, testing patterns, and clinical outcomes of first-line (1L) therapy for metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (mGC/GEJC/EAC).

Sign Up to like & get
recommendations! Published in 2024 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2024.42.3_suppl.275

Abstract: 275 Background: GC/GEJC/EAC are among the leading causes of cancer-related morbidity and mortality worldwide. Nivolumab + fluoropyrimidine- + platinum-containing chemotherapy (NIVO+chemo) has demonstrated superior efficacy in patients with advanced non-HER2-positive (HER2-) GC/GEJC/EAC versus chemo alone… read more here.

Keywords: cancer; mgc gejc; nivo chemo; gejc eac ... See more keywords

First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced gastroesophageal junction cancer (GEJC) and esophageal adenocarcinoma (EAC): Analysis of KEYNOTE-590 and KEYNOTE-859 by tumor type.

Sign Up to like & get
recommendations! Published in 2024 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2024.42.3_suppl.345

Abstract: 345 Background: First-line (1L) treatment of GEJC and EAC is similar to that for gastric adenocarcinomas, based on evidence from 2 large phase 3 gastric and esophageal cancer trials. The phase 3 KEYNOTE-590 trial (NCT03189719)… read more here.

Keywords: chemo; pembro chemo; keynote 590; keynote 859 ... See more keywords

PD-1 inhibitor (sintilimab) and fruquintinib plus SOX as conversion therapy for initially unresectable gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a single-arm, phase 2 clinical trial.

Sign Up to like & get
recommendations! Published in 2025 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2025.43.4_suppl.406

Abstract: 406 Background: The evidence of conversion therapy for unresectable GC/GEJC is limited. Previously, preliminary results of the ongoing open-label, phase 2 study (NCT05177068) have showed promising R0 surgical conversion rate (62.1%), R0 resection rate (100%)… read more here.

Keywords: rate; conversion; plus sox; sintilimab ... See more keywords